{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:35:07Z","timestamp":1790274907000,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s12325-023-02529-7","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T14:02:18Z","timestamp":1685109738000},"page":"2965-2984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Roadmap for the Management of Type\u00a02 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5875-0950","authenticated-orcid":false,"given":"Yousef","family":"Al Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Al Busaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Al Dahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5992-1881","authenticated-orcid":false,"given":"Munawar","family":"Almajnoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5422-155X","authenticated-orcid":false,"given":"Al Saeed","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7856-9753","authenticated-orcid":false,"given":"Khalid","family":"Alshali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3443-001X","authenticated-orcid":false,"given":"Mostafa","family":"Al-Shamiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saud","family":"Al Sifri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6664-4584","authenticated-orcid":false,"given":"Mohammed","family":"Arafah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7031-7594","authenticated-orcid":false,"given":"Siew Pheng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"El-Tamimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3632-4336","authenticated-orcid":false,"given":"Khadija","family":"Hafidh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6598-6972","authenticated-orcid":false,"given":"Mohamed","family":"Hassanein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Shaaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7265-4279","authenticated-orcid":false,"given":"Ali","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"2529_CR1","unstructured":"World Health Organization. Cardiovascular diseases (CVDs). 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds). Accessed Oct 24, 2022."},{"key":"2529_CR2","unstructured":"International Diabetes Federation. IDF diabetes atlas, 10th edition. 2021. Brussels, Belgium. https:\/\/www.diabetesatlas.org. Accessed Oct 18, 2022."},{"key":"2529_CR3","first-page":"1303","volume":"21","author":"SA Meo","year":"2017","unstructured":"Meo SA, Usmani AM, Qalbani E. Prevalence of type\u00a02 diabetes in the Arab world: impact of GDP and energy consumption. Eur Rev Med Pharmacol Sci. 2017;21:1303\u201312.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2529_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"NCD Risk Factor Collaboration","year":"2021","unstructured":"NCD Risk Factor Collaboration. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957\u201380.","journal-title":"Lancet"},{"key":"2529_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41371-021-00554-z","volume":"36","author":"M Abboud","year":"2022","unstructured":"Abboud M, Karam S. Hypertension in the Middle East: current state, human factors, and barriers to control. J Hum Hypertens. 2022;36:428\u201336.","journal-title":"J Hum Hypertens"},{"key":"2529_CR6","first-page":"345","volume":"9","author":"AA Al-Rasheedi","year":"2015","unstructured":"Al-Rasheedi AA. Glycemic control among patients with type\u00a02 diabetes mellitus in countries of Arabic Gulf. Int J Health Sci (Qassim). 2015;9:345\u201350.","journal-title":"Int J Health Sci (Qassim)"},{"key":"2529_CR7","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s13300-022-01282-4","volume":"13","author":"M Hassanein","year":"2022","unstructured":"Hassanein M, Akbar MAJ, Al-Shamiri M, et al. Management of diabetes and hypertension within the Gulf Region: updates on treatment practices and therapies. Diabetes Ther. 2022;13:1253\u201380.","journal-title":"Diabetes Ther"},{"key":"2529_CR8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.15537\/smj.2021.42.5.20200676","volume":"42","author":"MZ Aljulifi","year":"2021","unstructured":"Aljulifi MZ. Prevalence and reasons of increased type\u00a02 diabetes in Gulf Cooperation Council Countries. Saudi Med J. 2021;42:481\u201390.","journal-title":"Saudi Med J"},{"key":"2529_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.diabres.2019.03.024","volume":"151","author":"MB Gomes","year":"2019","unstructured":"Gomes MB, Rathmann W, Charbonnel B, et al. Treatment of type\u00a02 diabetes mellitus worldwide: baseline patient characteristics in the global DISCOVER study. Diabetes Res Clin Pract. 2019;151:20\u201332.","journal-title":"Diabetes Res Clin Pract"},{"key":"2529_CR10","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2337\/dc20-2439","volume":"44","author":"M Lind","year":"2021","unstructured":"Lind M, Imberg H, Coleman RL, Nerman O, Holman RR. Historical HbA1c values may explain the type\u00a02 diabetes legacy effect: UKPDS 88. Diabetes Care. 2021;44:2231\u20137.","journal-title":"Diabetes Care"},{"key":"2529_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type\u00a02 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405\u201312.","journal-title":"BMJ"},{"key":"2529_CR12","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2337\/dc17-1144","volume":"42","author":"N Laiteerapong","year":"2019","unstructured":"Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type\u00a02 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2019;42:416\u201326.","journal-title":"Diabetes Care"},{"key":"2529_CR13","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s00125-021-05539-8","volume":"64","author":"R Folz","year":"2021","unstructured":"Folz R, Laiteerapong N. The legacy effect in diabetes: are there long-term benefits? Diabetologia. 2021;64:2131\u20137.","journal-title":"Diabetologia"},{"key":"2529_CR14","unstructured":"International Diabetes Federation. IDF clinical practice recommendations for managing type\u00a02 diabetes in primary care. 2017. https:\/\/idf.org\/e-library\/guidelines.html. Accessed Oct 19, 2022."},{"key":"2529_CR15","unstructured":"National Institute for Health and Care Excellence. Type\u00a02 diabetes in adults: management. 2015. https:\/\/www.nice.org.uk\/guidance\/ng28. Accessed Oct 19, 2022."},{"key":"2529_CR16","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.2337\/dc22-S006","volume":"45","author":"B Draznin","year":"2022","unstructured":"Draznin B, Aroda VR, Bakris G, et al. Glycemic targets: standards of medical care in diabetes\u20142022. Diabetes Care. 2022;45:S83\u201396.","journal-title":"Diabetes Care"},{"key":"2529_CR17","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type\u00a02 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925\u201366.","journal-title":"Diabetologia"},{"key":"2529_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255\u2013323.","journal-title":"Eur Heart J"},{"key":"2529_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/dom.13866","volume":"22","author":"K Khunti","year":"2020","unstructured":"Khunti K, Chen H, Cid-Ruzafa J, et al. Glycaemic control in patients with type\u00a02 diabetes initiating second-line therapy: results from the global DISCOVER study programme. Diabetes Obes Metab. 2020;22:66\u201378.","journal-title":"Diabetes Obes Metab"},{"key":"2529_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.diabres.2019.01.017","volume":"149","author":"A Jabbar","year":"2019","unstructured":"Jabbar A, Abdallah K, Hassoun A, et al. Patterns and trends in insulin initiation and intensification among patients with type\u00a02 diabetes mellitus in the Middle East and North Africa region. Diabetes Res Clin Pract. 2019;149:18\u201326.","journal-title":"Diabetes Res Clin Pract"},{"key":"2529_CR21","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc22-S009","volume":"45","author":"B Draznin","year":"2022","unstructured":"Draznin B, Aroda VR, Bakris G, et al. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142022. Diabetes Care. 2022;45:S125\u201343.","journal-title":"Diabetes Care"},{"key":"2529_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2337\/dci19-0066","volume":"43","author":"JB Buse","year":"2020","unstructured":"Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type\u00a02 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43:487\u201393.","journal-title":"Diabetes Care"},{"key":"2529_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012356","volume":"8","author":"D Giugliano","year":"2019","unstructured":"Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Esposito K. Glycemic control, preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type\u00a02 diabetes mellitus: systematic review with meta-analysis of cardiovascular outcome trials and intensive glucose control trials. J Am Heart Assoc. 2019;8: e012356.","journal-title":"J Am Heart Assoc"},{"key":"2529_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type\u00a02 diabetes: a meta-analysis. JAMA Cardiol. 2021;6:148\u201358.","journal-title":"JAMA Cardiol"},{"key":"2529_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type\u00a02 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20:189.","journal-title":"Cardiovasc Diabetol"},{"key":"2529_CR26","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/M20-0864","volume":"173","author":"A Tsapas","year":"2020","unstructured":"Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type\u00a02 diabetes: a systematic review and network meta-analysis. Ann Intern Med. 2020;173:278\u201386.","journal-title":"Ann Intern Med"},{"key":"2529_CR27","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/cpt.1307","volume":"105","author":"A Maloney","year":"2019","unstructured":"Maloney A, Rosenstock J, Fonseca V. A model-based meta-analysis of 24 antihyperglycemic drugs for type\u00a02 diabetes: comparison of treatment effects at therapeutic doses. Clin Pharmacol Ther. 2019;105:1213\u201323.","journal-title":"Clin Pharmacol Ther"},{"key":"2529_CR28","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/j.1742-1241.2011.02797.x","volume":"65","author":"S Al Sifri","year":"2011","unstructured":"Al Sifri S, Basiounny A, Echtay A, et al. The incidence of hypoglycaemia in Muslim patients with type\u00a02 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011;65:1132\u201340.","journal-title":"Int J Clin Pract"},{"key":"2529_CR29","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1185\/03007995.2012.707119","volume":"28","author":"SR Aravind","year":"2012","unstructured":"Aravind SR, Ismail SB, Balamurugan R, et al. Hypoglycemia in patients with type\u00a02 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr Med Res Opin. 2012;28:1289\u201396.","journal-title":"Curr Med Res Opin"},{"key":"2529_CR30","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1111\/dom.14169","volume":"22","author":"F Zaccardi","year":"2020","unstructured":"Zaccardi F, Jacquot E, Cortese V, et al. Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type\u00a02 diabetes. Diabetes Obes Metab. 2020;22:2417\u201326.","journal-title":"Diabetes Obes Metab"},{"key":"2529_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S2213-8587(14)70213-X","volume":"3","author":"SH Simpson","year":"2015","unstructured":"Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015;3:43\u201351.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2529_CR32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/ki.2012.401","volume":"83","author":"V Perkovic","year":"2013","unstructured":"Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves kidney outcomes in patients with type\u00a02 diabetes. Kidney Int. 2013;83:517\u201323.","journal-title":"Kidney Int"},{"key":"2529_CR33","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1007\/s13300-021-01059-1","volume":"12","author":"Y Al-Saleh","year":"2021","unstructured":"Al-Saleh Y, Sabico S, Al-Furqani A, et al. Sulfonylureas in the current practice of type\u00a02 diabetes management: are they all the same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on sulfonylureas. Diabetes Ther. 2021;12:2115\u201332.","journal-title":"Diabetes Ther"},{"key":"2529_CR34","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1080\/14656566.2022.2141108","volume":"23","author":"B Tomlinson","year":"2022","unstructured":"Tomlinson B, Li YH, Chan P. Evaluating gliclazide for the treatment of type\u00a02 diabetes mellitus. Expert Opin Pharmacother. 2022;23:1869\u201377.","journal-title":"Expert Opin Pharmacother"},{"key":"2529_CR35","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.diabres.2010.05.012","volume":"89","author":"S Zoungas","year":"2010","unstructured":"Zoungas S, Chalmers J, Kengne AP, et al. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract. 2010;89:126\u201333.","journal-title":"Diabetes Res Clin Pract"},{"key":"2529_CR36","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/dom.12700","volume":"18","author":"D Schrijnders","year":"2016","unstructured":"Schrijnders D, Wever R, Kleefstra N, et al. Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (ZODIAC-39). Diabetes Obes Metab. 2016;18:973\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"2529_CR37","unstructured":"Servier. Type\u00a02 diabetes mellitus oral agent's fact checking. 2022. Servier. https:\/\/medicallearninghub.com\/course\/type-2-diabetes-mellitus-oral-agents-fact-checking. Accessed Oct 25, 2022."},{"key":"2529_CR38","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","volume":"392","author":"GBD 2017 Risk Factor Collaborators","year":"2018","unstructured":"GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1923\u201394.","journal-title":"Lancet"},{"key":"2529_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102830","volume":"9","author":"AA Alsheikh-Ali","year":"2014","unstructured":"Alsheikh-Ali AA, Omar MI, Raal FJ, et al. Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East Cardiovascular Epidemiological (ACE) study. PLoS ONE. 2014;9: e102830.","journal-title":"PLoS ONE"},{"key":"2529_CR40","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1097\/HJH.0000000000001326","volume":"35","author":"AM Yusufali","year":"2017","unstructured":"Yusufali AM, Khatib R, Islam S, et al. Prevalence, awareness, treatment and control of hypertension in four Middle East countries. J Hypertens. 2017;35:1457\u201364.","journal-title":"J Hypertens"},{"key":"2529_CR41","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"JT Wright Jr","year":"2002","unstructured":"Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421\u201331.","journal-title":"JAMA"},{"key":"2529_CR42","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1161\/01.HYP.0000070905.09395.F6","volume":"41","author":"S Oparil","year":"2003","unstructured":"Oparil S. Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT): practical implications. Hypertension. 2003;41:1006\u20139.","journal-title":"Hypertension"},{"key":"2529_CR43","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"W Zhang","year":"2021","unstructured":"Zhang W, Zhang S, Deng Y, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385:1268\u201379.","journal-title":"N Engl J Med"},{"key":"2529_CR44","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1291\/hypres.31.2115","volume":"31","author":"JATOS Study Group","year":"2008","unstructured":"JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31:2115\u201327.","journal-title":"Hypertens Res"},{"key":"2529_CR45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.37616\/2212-5043.1328","volume":"35","author":"W Alhabeeb","year":"2023","unstructured":"Alhabeeb W, Tash AA, Alshamiri M, et al. National Heart Center\/Saudi Heart Association 2023 guidelines on the management of hypertension. J Saudi Heart Assoc. 2023;35:16\u201339.","journal-title":"J Saudi Heart Assoc"},{"key":"2529_CR46","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71:e13\u2013115.","journal-title":"Hypertension"},{"key":"2529_CR47","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"2529_CR48","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334\u201357.","journal-title":"Hypertension"},{"key":"2529_CR49","unstructured":"World Health Organization. Guideline for the pharmacological treatment of hypertension in adults. 2021. World Health Organization, Geneva. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/344424\/9789240033986-eng.pdf. Accessed Oct 24, 2022."},{"key":"2529_CR50","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903\u201313.","journal-title":"Lancet"},{"key":"2529_CR51","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367.","journal-title":"Lancet"},{"key":"2529_CR52","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103\u201316.","journal-title":"N Engl J Med"},{"key":"2529_CR53","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"BPLTT Collaboration","year":"2021","unstructured":"Collaboration BPLTT. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397:1625\u201336.","journal-title":"Lancet"},{"key":"2529_CR54","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1093\/ajh\/hpu002","volume":"27","author":"J Brguljan-Hitij","year":"2014","unstructured":"Brguljan-Hitij J, Thijs L, Li Y, et al. Risk stratification by ambulatory blood pressure monitoring across JNC classes of conventional blood pressure. Am J Hypertens. 2014;27:956\u201365.","journal-title":"Am J Hypertens"},{"key":"2529_CR55","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1093\/eurheartj\/ehx760","volume":"39","author":"MH Mehlum","year":"2018","unstructured":"Mehlum MH, Liest\u00f8l K, Kjeldsen SE, et al. Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. Eur Heart J. 2018;39:2243\u201351.","journal-title":"Eur Heart J"},{"key":"2529_CR56","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1097\/HJH.0000000000002598","volume":"38","author":"E Campana","year":"2020","unstructured":"Campana E, Cunha V, Glaveckaite S, et al. The use of single-pill combinations as first-line treatment for hypertension: translating guidelines into clinical practice. J Hypertens. 2020;38:2369\u201377.","journal-title":"J Hypertens"},{"key":"2529_CR57","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ijcard.2021.01.070","volume":"331","author":"G Parati","year":"2021","unstructured":"Parati G, Lombardi C, Pengo M, Bilo G, Ochoa JE. Current challenges for hypertension management: from better hypertension diagnosis to improved patients\u2019 adherence and blood pressure control. Int J Cardiol. 2021;331:262\u20139.","journal-title":"Int J Cardiol"},{"key":"2529_CR58","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1097\/HJH.0b013e328348c934","volume":"29","author":"J Redon","year":"2011","unstructured":"Redon J, Erdine S, B\u00f6hm M, et al. Physician attitudes to blood pressure control: findings from the Supporting Hypertension Awareness and Research Europe-wide survey. J Hypertens. 2011;29:1633\u201340.","journal-title":"J Hypertens"},{"key":"2529_CR59","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1097\/HJH.0000000000002783","volume":"39","author":"DH Ali","year":"2021","unstructured":"Ali DH, Kili\u00e7 B, Hart HE, et al. Therapeutic inertia in the management of hypertension in primary care. J Hypertens. 2021;39:1238\u201345.","journal-title":"J Hypertens"},{"key":"2529_CR60","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1161\/CIRCRESAHA.118.313220","volume":"124","author":"M Burnier","year":"2019","unstructured":"Burnier M, Egan BM. Adherence in hypertension: a review of prevalence, risk factors, impact, and management. Circ Res. 2019;124:1124\u201340.","journal-title":"Circ Res"},{"key":"2529_CR61","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1751-7176.2010.00322.x","volume":"12","author":"P Bramlage","year":"2010","unstructured":"Bramlage P, B\u00f6hm M, Volpe M, et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens (Greenwich). 2010;12:666\u201377.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2529_CR62","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/jhh.2009.76","volume":"24","author":"M Thoenes","year":"2010","unstructured":"Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, B\u00f6hm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens. 2010;24:336\u201344.","journal-title":"J Hum Hypertens"},{"key":"2529_CR63","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1161\/HYPERTENSIONAHA.116.08729","volume":"69","author":"P Gupta","year":"2017","unstructured":"Gupta P, Patel P, \u0160trauch B, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension. 2017;69:1113\u201320.","journal-title":"Hypertension"},{"key":"2529_CR64","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ajh\/hpab108","volume":"35","author":"BI L\u00e9vy","year":"2022","unstructured":"L\u00e9vy BI, Mourad JJ. Renin angiotensin blockers and cardiac protection: from basics to clinical trials. Am J Hypertens. 2022;35:293\u2013302.","journal-title":"Am J Hypertens"},{"key":"2529_CR65","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40119-019-00150-w","volume":"8","author":"A Ancion","year":"2019","unstructured":"Ancion A, Tridetti J, Nguyen Trung ML, Oury C, Lancellotti P. A review of the role of bradykinin and nitric oxide in the cardioprotective action of angiotensin-converting enzyme inhibitors: focus on perindopril. Cardiol Ther. 2019;8:179\u201391.","journal-title":"Cardiol Ther"},{"key":"2529_CR66","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","volume":"33","author":"LC van Vark","year":"2012","unstructured":"van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33:2088\u201397.","journal-title":"Eur Heart J"},{"key":"2529_CR67","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1161\/CIRCULATIONAHA.117.026112","volume":"135","author":"MH Strauss","year":"2017","unstructured":"Strauss MH, Hall AS. Angiotensin receptor blockers do not reduce risk of myocardial infarction, cardiovascular death, or total mortality: further evidence for the ARB-MI paradox. Circulation. 2017;135:2088\u201390.","journal-title":"Circulation"},{"key":"2529_CR68","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1161\/CIRCULATIONAHA.105.594986","volume":"114","author":"MH Strauss","year":"2006","unstructured":"Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006;114:838\u201354.","journal-title":"Circulation"},{"key":"2529_CR69","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/hrt.2006.107185","volume":"93","author":"AS Hall","year":"2007","unstructured":"Hall AS, Strauss MH. More about the \u201cARB MI paradox.\u201d Heart. 2007;93:1011\u20134.","journal-title":"Heart"},{"key":"2529_CR70","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40256-016-0173-4","volume":"16","author":"S Taddei","year":"2016","unstructured":"Taddei S, Bortolotto L. Unraveling the pivotal role of bradykinin in ACE inhibitor activity. Am J Cardiovasc Drugs. 2016;16:309\u201321.","journal-title":"Am J Cardiovasc Drugs"},{"key":"2529_CR71","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2147\/VHRM.S17207","volume":"7","author":"JM Flack","year":"2011","unstructured":"Flack JM, Nasser SA. Benefits of once-daily therapies in the treatment of hypertension. Vasc Health Risk Manag. 2011;7:777\u201387.","journal-title":"Vasc Health Risk Manag"},{"key":"2529_CR72","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahl\u00f6f","year":"2005","unstructured":"Dahl\u00f6f B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895\u2013906.","journal-title":"Lancet"},{"key":"2529_CR73","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(18)31776-8","volume":"392","author":"A Gupta","year":"2018","unstructured":"Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018;392:1127\u201337.","journal-title":"Lancet"},{"key":"2529_CR74","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF03256570","volume":"9","author":"VK Bahl","year":"2009","unstructured":"Bahl VK, Jadhav UM, Thacker HP. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study. Am J Cardiovasc Drugs. 2009;9:135\u201342.","journal-title":"Am J Cardiovasc Drugs"},{"key":"2529_CR75","doi-asserted-by":"publisher","first-page":"31","DOI":"10.18087\/cardio.2019.10.n731","volume":"59","author":"MG Glezer","year":"2019","unstructured":"Glezer MG. Antihypertensive effect of switching to a fixed perindopril\/amlodipine combination in patients ineffectively treated by free sartan-containing combinations. Results of the AVANGARD Study [in Russian]. Kardiologiia. 2019;59:31\u20138.","journal-title":"Kardiologiia"},{"key":"2529_CR76","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s12325-020-01527-3","volume":"38","author":"CA D\u00e9zsi","year":"2021","unstructured":"D\u00e9zsi CA, Glezer M, Karpov Y, Brzozowska-Villatte R, Farsang C. Effectiveness of perindopril\/indapamide single-pill combination in uncontrolled patients with hypertension: a pooled analysis of the FORTISSIMO, FORSAGE, ACES and PICASSO observational studies. Adv Ther. 2021;38:479\u201394.","journal-title":"Adv Ther"},{"key":"2529_CR77","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40256-014-0067-2","volume":"14","author":"K T\u00f3th","year":"2014","unstructured":"T\u00f3th K. Antihypertensive efficacy of triple combination perindopril\/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14:137\u201345.","journal-title":"Am J Cardiovasc Drugs"},{"key":"2529_CR78","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1161\/HYPERTENSIONAHA.113.02252","volume":"63","author":"J Chalmers","year":"2014","unstructured":"Chalmers J, Arima H, Woodward M, et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type\u00a02 diabetes mellitus: results from the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension. 2014;63:259\u201364.","journal-title":"Hypertension"},{"issue":"24","key":"2529_CR79","doi-asserted-by":"publisher","first-page":"5921","DOI":"10.3390\/jcm10245921","volume":"10","author":"AFG Cicero","year":"2021","unstructured":"Cicero AFG, Fogacci F, Rizzoli E, D\u2019Addato S, Borghi C. Long-term impact of different triple combination antihypertensive medications on blood pressure control, metabolic pattern and incident events: data from the Brisighella Heart Study. J Clin Med. 2021;10(24):5921.","journal-title":"J Clin Med"},{"key":"2529_CR80","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368.","journal-title":"Lancet"},{"key":"2529_CR81","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12325-021-01958-6","volume":"39","author":"M Abeel","year":"2022","unstructured":"Abeel M, Gupta A, Constance C. Concomitant treatment of hypertensive patients with bisoprolol and perindopril in routine clinical practice: a post hoc analysis of the CONFIDENCE II, PROTECT I, and PROTECT III observational studies. Adv Ther. 2022;39:391\u2013404.","journal-title":"Adv Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02529-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02529-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02529-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T05:17:54Z","timestamp":1686806274000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02529-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":81,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["2529"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02529-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"assertion":[{"value":"27 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}